Treatment guidelines for hypercholesterolaemia: Time to consider soluble fibre

International Journal of Clinical Practice

Volumn 53, Issue 5, 1999, Pages 369-372

  MacMahon, M ^a,b  

^a St Mark's Hospital   (United Kingdom)

^b Chiltern International Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; ISPAGULA;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DIET; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANTILIPEMIC AGENTS; DIET; DIETARY FIBER; HUMANS; HYPERCHOLESTEROLEMIA; PATIENT ACCEPTANCE OF HEALTH CARE; PRACTICE GUIDELINES;

EID: 0032815478     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kannel WB, Castelli W, Gordon T, McNamara PM. Serum cholesterol lipoproteins and risk of coronary heart disease: the Framingham Study. Ann Intern Med 1971; 74: 1-12.
2. Kannel WB, Gordon T, Castelli WP. Role of lipid and lipoprotein fractions in assessing atherogenesis: the Framingham Study. Progr Lipid Res 1981; 20: 339-348.
3. Martin MJ, Hulley SB, Browner WS et al. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361,662 men. Lancet 1986; ii: 933-936.
4. Castelli WP, Garrison RJ, Wilson PWF et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. JAMA 1986; 256: 2835-2838.
5. Shepherd J, Cobbe SM, Ford I et al, for the West of Scotland Coronary Prevention Study (WOSCOPS) Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
7. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-373.
8. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-1503.
9. Wood D, Durrington P, Poulter N et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(suppl 2): S1-S26.
10. Standing Medical Advisory Committee. The use of statins. London: Department of Health, 1997.
11. Ramsay LE, Haq IU, Jackson PR et al. Targeting lipid-lowering drug therapy for primary prevention of coronary heart disease: an updated Sheffield table. Lancet 1996; 348: 387-388.
12. McLeod AJ, Armitage M. Use of statins. BMJ 1998; 317: 474 (letter).
13. National Heart Foundation. Clinical guidelines for the assessment and management of dyslipidaemia. NZ Med J 1996; 109: 224-232.
14. Rivellese AA. Long term metabolic effects of two dietary methods of treating hyperlipidaemia. BMJ 1994; 308: 227-231.
15. Ramsay L, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. BMJ 1991; 303: 953-957.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 1993; 269: 3015-3023.
17. Neil HAW, Roe L, Godlee RJP et al. Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ 1995; 310: 569-573
18. Glore SR, van Treeck D, Knehans AW, Guild M. Soluble fiber and serum lipids: a literature review. J Am Diet Assoc 1994; 94: 425-436.
19. Rimm EB, Ascherio A, Giovannucci E et al. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 1996; 275: 447-451.
20. Pietinen P, Rimm EB, Korhonen P et al. Intake of dietary fiber and risk of coronary heart disease in a cohort of Finnish men. Circulation 1996; 94: 2720-2727.
21. Roberts DCR, Truswell AS, Bencke A et al. The cholesterol-lowering effect of a breakfast cereal containing psyllium fiber. Med J Aust 1994; 161: 660-664.
22. MacMahon M, Carless J. Ispaghula husk in the treatment of hypercholesterolaemia: a double-blind controlled study. J Cardiovasc Risk 1998; 5: 167-172.
23. Anderson JW, Floore TL, Geil PB et al. Hypercholesterolemic effects of different bulk-forming hydrophilic fibres as adjuncts to dietary therapy in mild to moderate hypercholesterolemia. Arch Intern Med 1991; 1151: 1597-1602.
24. Field K, Thorogood M, Silagy C et al. Strategies for reducing coronary risk factors in primary care: which is most cost effective? BMJ 1995; 310: 1109-1112.
25. Gregory J, Foster K, Tyler H, Wiseman M. The dietary and nutritional survey of British adults: a survey of the dietary behaviour, nutritional status and blood pressure of adults aged 16-24. London: HMSO, 1990.
26. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443-1448.
27. Freemantle N, Barbour R, Johnson R et al. The use of statins: a case of misleading priorities? BMJ 1997; 315: 826-828.